Tracer library / [212Pb]Pb-DOTA-Re(Arg11)CCMSH

[212Pb]Pb-DOTA-Re(Arg11)CCMSH

Also written as [212Pb]Pb-DOTA-Re(Arg11)CCMSH
Radionuclide
Pb-212
Modality
—
Production route
—
Stage
Preclinical
Syntheses indexed
0
MelanomaOther radioligand therapy

What it is

Compound class
alpha-melanocyte-stimulating hormone (α-MSH) peptide analog conjugated with DOTA chelator
Target / mechanism
Melanocortin-1 receptor (MC1-R) and melanin PMID 18387816
Clinical application
Targeted alpha-particle radionuclide therapy of melanoma PMID 16061880
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [212Pb]Pb-DOTA-Re(Arg11)CCMSH, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 2 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 16061880, 18387816. Stage set/updated at stage 39 from PMID 16061880: 'Biodistribution and therapy studies were done in the B16/F1 melanoma-bearing C57 mouse flank tumor model.'.